Genetic Risk Assessment and Testing for GI Cancers and Polyposis

Genetic risk assessment and testing for gastrointestinal (GI) cancers and polyposis syndromes are critical components of modern clinical practice. They aim to identify individuals and families at increased risk of developing hereditary cancer syndromes, enabling targeted prevention, early detection, and personalized management strategies. Below is a detailed overview addressing genetic risk assessment and testing for GI cancers and polyposis:

### **1. Clinical Importance of Genetic Risk Assessment**

Gastrointestinal clinicians play a pivotal role in identifying patients with hereditary cancer syndromes. These syndromes predispose individuals to colorectal, gastric, pancreatic, and other GI cancers. Early identification allows for tailored surveillance, risk-reducing interventions, and improved outcomes.

### **2. Underutilization of Genetic Testing**

Despite advancements in sequencing technologies and reduced costs, genetic testing remains underutilized. This results in missed opportunities to identify high-risk individuals and families who could benefit from preventive care.

### **3. Barriers to Genetic Testing Integration**

Several barriers limit the integration of genetic testing into routine GI practice:

• **Lack of awareness** among healthcare providers and patients.
• **Cost concerns** despite decreasing prices of testing.
• **Limited access to genetic counseling services** for interpretation and guidance.
• **Absence of structured implementation pathways** in healthcare systems.

### **4. Prevalence of Genetic Risk**

Approximately **1 in 20 GI patients presenting for endoscopy** meet criteria for genetic evaluation for a cancer susceptibility syndrome. This highlights the importance of systematic risk assessment in GI clinics.

### **5. Common Hereditary Syndromes and Their Management**

#### **Lynch Syndrome**

• Caused by mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2, EPCAM).
• The most common hereditary colorectal cancer syndrome, affecting **1 in 279 individuals**.
• **Screening Recommendations:** Surveillance colonoscopy every 1–3 years starting in early adulthood significantly reduces mortality. Additional screening for gastric and pancreatic cancers may be indicated.
• **Chemoprevention:** Daily aspirin use has been shown to reduce colorectal cancer risk by 44% in Lynch syndrome patients.

#### **Familial Adenomatous Polyposis (FAP)**

• Caused by mutations in the APC gene.
• Characterized by hundreds to thousands of adenomas in the colon.
• **Screening Recommendations:** Early colonoscopy starting at age 10–15 and eventual colectomy based on polyp burden.

#### **MUTYH-Associated Polyposis (MAP)**

• Inherited recessively due to mutations in the MUTYH gene.
• Presents with fewer adenomas (10–100).
• **Screening Recommendations:** Colonoscopy every 1–2 years; surgery may be required for extensive disease.

#### **Hamartomatous Polyposis Syndromes**

• Includes Juvenile Polyposis Syndrome and Peutz-Jeghers Syndrome.
• Associated with elevated risks for colorectal, gastric, pancreatic, and other cancers.
• **Screening Recommendations:** Require both colonoscopic and upper GI surveillance.

#### **Serrated Polyposis Syndrome**

• Defined clinically by multiple serrated lesions.
• **Screening Recommendations:** Colonoscopy every 1–3 years.
• Most cases lack identifiable germline variants, though RNF43 mutations are occasionally implicated.

#### **Gastric Cancer Syndromes**

• Mutations in CDH1 and CTNNA1 genes increase risk for diffuse-type gastric cancers.
• **Management:** Prophylactic gastrectomy is often recommended but may be replaced by intensive surveillance in select cases.

#### **Pancreatic Cancer Risk Genes**

• High-risk mutations include STK11, CDKN2A, BRCA1/2, PALB2, and ATM.
• **Screening Recommendations:** MRI or endoscopic ultrasound (EUS) annually from ages 45–50, or earlier depending on family history.

### **6. Risk Assessment Process**

Comprehensive risk assessment involves:

• Collecting a detailed family history, including first- and second-degree relatives.
• Tumor-based MMR testing to identify hereditary cancer risk.

### **7. Genetic Testing and Multi-Gene Panel Testing (MGPT)**

• **Multi-Gene Panel Testing (MGPT):** MGPT has replaced single-gene testing, improving the detection of germline pathogenic variants. About **10–15% of GI cancer patients** have detectable pathogenic variants.
• **Variants of Uncertain Significance (VUS):** Roughly 41% of individuals undergoing MGPT have at least one VUS, most of which are later reclassified as benign. VUS should not alter clinical management.

### **8. Psychological and Ethical Considerations**

• Genetic testing rarely causes severe psychological harm but may increase anxiety in patients.
• Ethical concerns include ensuring equitable access to testing and protecting patients from insurance discrimination.

### **9. Cascade Testing**

• Testing first-degree relatives of affected individuals is essential for identifying hereditary cancer syndromes.
• Despite its importance, cascade testing is underused, with only about **52% of eligible relatives undergoing testing**.
• Provider-mediated outreach has been shown to improve uptake.

### **10. Emerging Technologies and Future Integration**

• **Emerging Technologies:** Artificial intelligence, polygenic risk scores, and long-read sequencing are advancing precision in identifying genetic risk and reclassifying uncertain variants.
• **Future Integration:** Genetic testing should become standard practice in GI clinics through mainstreaming, telehealth, and point-of-care models. Every patient should receive family history screening and appropriate genetic referrals.

### **Key Takeaways for Clinicians**

1. **Identify High-Risk Patients:** Use family history and tumor-based testing to assess hereditary cancer risk.

2. **Implement Surveillance Protocols:** Tailor screening for colorectal, gastric, and pancreatic cancers based on genetic syndrome.

3. **Promote Genetic Testing:** Advocate for MGPT to detect germline pathogenic variants and guide management.

4. **Encourage Cascade Testing:** Ensure relatives of affected individuals are tested to identify at-risk family members.

5. **Leverage Emerging Technologies:** Incorporate AI and advanced sequencing tools to enhance precision and efficiency in genetic risk assessment.

6. **Address Barriers:** Work to overcome cost, access, and awareness challenges to integrate genetic testing into routine GI practice.

By adopting these strategies, clinicians can optimize care for patients with hereditary GI cancer syndromes, reduce cancer incidence, and improve survival outcomes.